Anturane Related Published Studies
Well-designed clinical trials related to Anturane (Sulfinpyrazone)
The effect of sulfinpyrazone on treadmill exercise-induced angina pectoris. [1993]
Well-designed clinical trials possibly related to Anturane (Sulfinpyrazone)
Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. [2004.08]
Use of cumulative meta-analysis in the design, monitoring, and final analysis of a clinical trial: a case study. [1995.10]
Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. [1990.01]
The effect of sulphinpyrazone and alpha-tocopherol on platelet activation and function in haemodialysed patients. [1990]
Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study. [1989.11]
Which role for antiplatelet and anticoagulant drugs in unstable angina pectoris? [1988.05]
A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone. [1987.05]
Other research related to Anturane (Sulfinpyrazone)
Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. [2000.12]
Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. [1998.08]
Acute renal failure due to sulfinpyrazone. [1998.05]
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. [1991.06.15]
[Effect of sulfinpyrazone on peritoneal and renal clearance in patients with chronic renal failure treated by intermittent peritoneal dialysis] [1990]
Other possibly related research studies
Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. [2004.11]
Ascorbate transport in pig coronary artery smooth muscle: Na(+) removal and oxidative stress increase loss of accumulated cellular ascorbate. [2000.09]
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. [1998.11]
Risks and benefits of drugs used in the management and prevention of gout. [1994.10]
[Antiplatelet therapy in cardiac diseases] [1992.02]
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method] [1992.02]
Influence of antiplatelet drugs on occlusion of arteriovenous fistula in uraemic patients. [1992]
[Platelet antiaggregants in the treatment of arterial thrombosis] [1991.10]
Aspirin in transient ischemic attacks and minor stroke: a meta-analysis. [1991.06]
Use of Rabenid for different indications. [1991]
Antiplatelet therapy in the prevention of stroke. [1991]
Clinical profile, therapeutic approach and outcome of gouty arthritis in northern India. [1990.06]
Human equivalent doses of platelet inhibitors and experimental atherosclerosis. [1990.05]
Sulphinpyrazone reduces endocardial injury and mural thrombosis. [1990.04]
Role of platelet inhibitor therapy in myocardial infarction. [1989.12]
Search for drugs that may reduce the load of neutrophil azurophilic granule enzymes in the lungs of patients with emphysema. [1989.07]
Issues in planning and interpreting active control equivalence studies. [1989]
Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials. [1988.04]
Anturan for secondary prophylaxis of myocardial infarction. [1988]
Effective antiplatelet drug concentrations in experimental arterial thromboembolism. [1987.11.01]
Serum urate levels and gout flares: analysis from managed care data. [2006.04]
Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. [2006.03]
Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. [2005.12]
Uric acid: role in cardiovascular disease and effects of losartan. [2004.03]
Aspirin and stroke prevention. [2003.06.15]
Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. [2001.02]
Von Willebrand's factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect. [2000.10]
Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease. [1999.08]
Diagnosis and management of gout. [1999.04.01]
A controlled letter intervention to change prescribing behavior: results of a dual-targeted approach. [1997.10]
Clinically important drug interactions with anticoagulants. An update. [1996.06]
Drugs and surgery in the prevention of ischemic stroke. [1995.01.26]
Interactions of warfarin with drugs and food. [1994.11.01]
Medical treatment for stroke prevention. [1994.07.01]
Antiplatelet therapy in the prevention of ischaemic stroke. [1994.06]
Platelet aggregation inhibitors in neurology. [1993.12.17]
The role of antiplatelet therapy in acute coronary syndromes and for secondary prevention following a myocardial infarction. [1993.07]
Clinical trials in stroke prevention. [1991.03]
[Hemolytic anemia in patients with heart valve prosthesis] [1990.03]
Antiplatelet agents in coronary artery disease. [1990.02]
Platelet inhibitor therapy. Agents and clinical implications. [1990.02]
[Clinical aspects of treatment and preventive treatment with thrombocyte aggregation inhibitors in cerebrovascular diseases] [1989]
Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. [1988.06]
Role of eicosanoids in the kappa-carrageenin rat tail thrombosis. [1988]
Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis. [1987.03]
Pharmacokinetic drug interactions with theophylline. [1984.07]
Potential drug-drug interactions within Veterans Affairs medical centers. [2007.07.15]
Disease-related and all-cause health care costs of elderly patients with gout. [2008.03]
MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. [2008.05]
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. [2008.10.08]
Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. [2008.12]
Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. [2008.05]
Adherence with urate-lowering therapies for the treatment of gout. [2009]
Development of a UGT1A1 reporter gene assay for induction studies: correlation between reporter gene data and regulation of UGT1A1 in human hepatocytes. [2010.01]
Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. [2009.07]
Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. [2011.02]
Utilization patterns of antihyperuricemic agents following safety announcement on
allopurinol and benzbromarone by Taiwan Food and Drug Administration. [2014]
Uricosuric medications for chronic gout. [2014]
|